PATENT CLAIM ANALYSIS

Application Number: 15779611
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "327000"]

Abstract:
The present invention relates to an improved formulation of danirixin in its hydrobromide salt form. This improved formulation can be an aqueous intravenous formulation containing danirixin or a lyophilized pharmaceutical solid composition containing danirixin to be reconstituted to provide a solution for intravenous administration.

Claim (Index 23):
The pharmaceutical composition according to  claim 19 , wherein the composition is freeze-dried to form a lyophilized powder.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 93.0
- Lexical Diversity: 1.39394
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14668683', '10553139', '13704145', '12370794', '16073580']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7216902786877538
- 35 USC 102 Novelty (BERT): 0.5044110426905715
- Combined Prediction Score: 0.6999623550880356
- Mean Citation Score: 172.468098
- Max Citation Score: 174.8063
- Similarity Product: 107.94575679885148

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test